AlgiPharma is a clinical stage biopharmaceutical company with a focus on developing its proprietary alginate technology for:

* Delivery platforms for nanoparticles, small and large molecule based drugs.

* Drug conjugates, adding functionality and reducing toxicity of parent compound.

* Stand alone API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

Our aim is to address unmet medical needs and fight diseases effectively through our innovative alginate technologies. Our alginate technology targets those diseases where there is a clinical need to mitigate abnormal mucus accumulation, non-invasive drug delivery challenges, microbial infection, biofilm formation and antibiotic resistance.